Literature DB >> 23100502

Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension.

Gianluigi Savarese1, Francesca Musella, Carmen D'Amore, Teresa Losco, Caterina Marciano, Paola Gargiulo, Giuseppe Rengo, Santo Dellegrottaglie, Eduardo Bossone, Dario Leosco, Pasquale Perrone-Filardi.   

Abstract

The purpose of this study was to clarify whether changes in cardiopulmonary haemodynamics induced by pharmacological therapy correlate with exercise capacity and clinical events in patients with pulmonary arterial hypertension. 16 randomised trials including 2353 patients, followed up for 16.4±10.6 weeks, measuring cardiopulmonary haemodynamics by right heart catheterisation and reporting clinical events were included. Meta-analysis and meta-regression analysis were performed to assess the effects of treatments on clinical events and the relationship between haemodynamic changes (pulmonary artery pressure, pulmonary vascular resistance, cardiac index and right atrial pressure) and clinical events. Treatments significantly reduced all-cause death (OR 0.5, 95% CI 0.3-0.7; p<0.01), hospitalisation for pulmonary arterial hypertension (OR 0.4, 95% CI 0.2-0.7; p<0.01), initiation of rescue therapy (OR 0.3, 95% CI 0.2-0.6; p<0.01) and the composite outcome (OR 0.3, 95% CI 0.3-0.5; p<0.01). No relationship was found between changes of haemodynamic parameters and clinical events, whereas changes of cardiac index and pulmonary vascular resistance significantly correlated with changes in the 6-min walking distance (r = 0.64, p = 0.03; r = -0.55, p = 0.04, respectively). In patients with pulmonary arterial hypertension, improvements of cardiopulmonary haemodynamics observed in randomised clinical trials correlate with exercise capacity changes but do not predict clinical events in a short-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100502     DOI: 10.1183/09031936.00123712

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Are hemodynamics surrogate end points in pulmonary arterial hypertension?

Authors:  Corey E Ventetuolo; Nicole B Gabler; Jason S Fritz; K Akaya Smith; Harold I Palevsky; James R Klinger; Scott D Halpern; Steven M Kawut
Journal:  Circulation       Date:  2014-06-20       Impact factor: 29.690

Review 2.  Medical treatment update on pulmonary arterial hypertension.

Authors:  Cher Y Enderby; Charles Burger
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

3.  Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Authors:  Paul M Hassoun; Roham T Zamanian; Rachel Damico; Noah Lechtzin; Rubina Khair; Todd M Kolb; Ryan J Tedford; Olivia L Hulme; Traci Housten; Chiara Pisanello; Takahiro Sato; Erica H Pullins; Celia P Corona-Villalobos; Stefan L Zimmerman; Mohamed A Gashouta; Omar A Minai; Fernando Torres; Reda E Girgis; Kelly Chin; Stephen C Mathai
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

4.  Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Authors:  Tim Lahm; Ivor S Douglas; Stephen L Archer; Harm J Bogaard; Naomi C Chesler; Francois Haddad; Anna R Hemnes; Steven M Kawut; Jeffrey A Kline; Todd M Kolb; Stephen C Mathai; Olaf Mercier; Evangelos D Michelakis; Robert Naeije; Rubin M Tuder; Corey E Ventetuolo; Antoine Vieillard-Baron; Norbert F Voelkel; Anton Vonk-Noordegraaf; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

5.  Experience with exercise right heart catheterization in the diagnosis of pulmonary hypertension: a retrospective study.

Authors:  Stephan Keusch; Anina Bucher; Séverine Müller-Mottet; Elisabeth Hasler; Marco Maggiorini; Rudolf Speich; Silvia Ulrich
Journal:  Multidiscip Respir Med       Date:  2014-10-15

6.  Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal.

Authors:  Max Schlueter; Amélie Beaudet; Evan Davies; Binu Gurung; Andreas Karabis
Journal:  BMC Pulm Med       Date:  2020-07-28       Impact factor: 3.317

7.  Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension.

Authors:  Jun Yang; Melanie K Nies; Zongming Fu; Rachel Damico; Frederick K Korley; Paul M Hassoun; David D Ivy; Eric D Austin; Allen D Everett
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

8.  Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.

Authors:  Cihangir Kaymaz; Ozgur Yasar Akbal; Aykun Hakgor; Hacer Ceren Tokgoz; Seda Tanyeri
Journal:  Pulm Circ       Date:  2018-05-16       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.